Get the Stockscreener App
41.30
1.00%
0.41
Pre-market:
41.71
0.41
+0.99%
Indivior Pharmaceuticals Inc stock is traded at $41.30, with a volume of 1.67M.
It is up +1.00% in the last 24 hours and up +7.95% over the past month.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
See More
Previous Close:
$40.89
Open:
$40.87
24h Volume:
1.67M
Relative Volume:
0.88
Market Cap:
$4.88B
Revenue:
$1.29B
Net Income/Loss:
$251.00M
P/E Ratio:
20.92
EPS:
1.9744
Net Cash Flow:
$-193.86M
1W Performance:
+3.77%
1M Performance:
+7.95%
6M Performance:
+16.53%
1Y Performance:
+172.79%
1-Day Range:
$40.67
$41.60
1-Week Range:
$39.20
$41.60
52-Week Range:
$15.00
$42.81
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Name
Indivior Pharmaceuticals Inc
Sector
Phone
804-379-1090
Address
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
41.30 | 4.88B | 1.29B | 251.00M | -193.86M | 1.9744 |
TAK
Takeda Pharmaceutical Co Adr
|
16.61 | 53.04B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.71 | 42.76B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.10 | 38.54B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.08 | 31.48B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
552.48 | 23.45B | 3.17B | 1.29B | 1.01B | 27.09 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Jul-22-25 | Resumed | Jefferies | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
View All
Indivior Pharmaceuticals Inc Stock (INDV) Latest News
Enterprise value to EBIT forward of Indivior Pharmaceuticals, Inc. – DUS:E7P - TradingView
How Indivior’s Multi-Index Russell 2000 Defensive Inclusion (INDV) Has Changed Its Investment Story - simplywall.st
Enterprise value to EBITDA forward of Indivior Pharmaceuticals, Inc. – DUS:E7P - TradingView
Is Indivior Pharmaceuticals (INDV) Fully Valued As Russell 2000 Index Additions Draw Buyers? - simplywall.st
Indivior Pharmaceuticals Inc. (INDV) is on the move, here's why the trend could be sustainable - MSN
Indivior Pharmaceuticals, Inc. Financial Disclosures & Filings - TradingView
Indivior’s Triple Russell 2000 Defensive Inclusion Could Be A Game Changer For Indivior Pharmaceuticals (INDV) - Yahoo Finance
Indivior added to Russell 2000 defensive indices, shares gain visibility with US investors - AD HOC NEWS
Does Indivior (INDV) Joining Multiple Russell 2000 Defensive Indices Recast Its Opioid-Treatment Narrative? - simplywall.st
Indivior Pharmaceuticals, Inc.(NasdaqGS:INDV) added to Russell 2000 Value-Defensive Index - marketscreener.com
Indivior Pharmaceuticals, Inc.(NasdaqGS:INDV) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Indivior Pharmaceuticals, Inc.(NasdaqGS: INDV) added to Russell 2000 Defensive Index - marketscreener.com
Indivior consensus shapes expectations, shares on Nasdaq under analyst scrutiny - AD HOC NEWS
INDV Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Indivior Pharmaceuticals, Inc. – NASDAQ:INDV - TradingView
Price to book forward of Indivior Pharmaceuticals, Inc. – NASDAQ:INDV - TradingView
Enterprise value to revenue forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
Price to sales forward of Indivior Pharmaceuticals, Inc. – NASDAQ:INDV - TradingView
Price to book forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
Price to sales forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
Enterprise value to EBITDA forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker - The Globe and Mail
Indivior Pharmaceuticals, Inc. Actuals & Estimates (LS:A42086) - TradingView
Indivior Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:INDV) - TradingView
Enterprise value to EBIT forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
Is Big Pharma's Patent Cliff Driving a New M&A Wave - Kavout | AI
Price to earnings forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
E7P Forecast — Price Target — Prediction for 2027 - TradingView
IBD 50 stock Indivior breaks out amid big fund ownership expansion, strong profit prospects - MSN
Reasons Why Investors Should Consider Betting on Indivior Stock - The Globe and Mail
A42086 Forecast — Price Target — Prediction for 2027 - TradingView
Indivior Pharmaceuticals (INDV) Pushes Cost Cuts And Growth, Is It Still 17% Undervalued? - Sahm
Form 4 Indivior PLC For: 23 June By Investing.com - Investing.com Australia
Indivior Pharmaceuticals (INDV) CEO vests 1.27M shares, 612K for taxes - Stock Titan
Indivior gains new overweight at Barclays on business turnaround - MSN
Does Indivior Pharmaceuticals Inc. (INDV) have the potential to rally 32.48% as Wall Street analysts expect? - MSN
Indivior Pharmaceuticals (INDV) Stock Could Be 23% Undervalued As Cost Cut Narrative Builds - Sahm
INDV News | INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) - ChartMill
INDIVIOR PHARMACEUTICALS INC (INDV) Stock Chart - ChartMill
Indivior stock gains new Overweight at Barclays (INDV:NASDAQ) - Seeking Alpha
Barclays Initiates Indivior at Overweight With $46 Price Target - marketscreener.com
Indivior PLC (INDV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Indivior PLC (INDV) Institutional Confidence - TradingKey
How Investors Are Reacting To Indivior (INDV) Upgraded 2026 Outlook And $175 Million Buyback Plan - Yahoo Finance
Suboxone Tooth Decay Lawsuit Updates for 2026 - Lawsuit Information Center
Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry? - Yahoo Finance
Is Indivior Pharmaceuticals, Inc. (INDV) A Good Stock To Buy Now? - Insider Monkey
Recent price trend in Indivior Pharmaceuticals Inc. (INDV) is your friend, here's why - MSN
Indivior Pharmaceuticals Inc (INDV) Insider Sell: Christian Heid - GuruFocus
Indivior (INDV) Chief Scientific Officer sells 18,586 shares under 10b5-1 plan - Stock Titan
INDV Stock: What Sublocade Growth Signals for 2026 - The Globe and Mail
Indivior Pharmaceuticals Inc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):